AN RCT OF AUTOLOGOUS STEM-CELL TRANSPLANTATION IN TREATMENT REFRACTORY CROHN’S DISEASE (LOW-INTENSITY THERAPY EVALUATION): ASTICLITE

James Lindsay*, Shahida Din, Chris Hawkey, Danny Hind, Alan Lobo, Yash Mahida, Gordon Moran, Miles Parkes, Jack Satsangi, See Subramanian, Lizzie Swaby, John Snowden.

1Barts Health NHS Trust, London, UK; 2Western General Hospital, Edinburgh, UK; 3University of Nottingham, Nottingham, UK; 4University of Sheffield, Sheffield, UK; 5Guy's and St Thomas' Hospital, London, UK; 6Cambridge University Hospitals, Cambridge, UK; 7Oxford University Hospitals, Oxford, UK; 8Royal Liverpool University Hospital, Liverpool, UK

10.1136/gutjnl-2021-BSG.6

Introduction Reports of benefit from HSCT were tempered by the ASTIC trial which failed its ambitious primary endpoint and reported high toxicity. Subsequent reports suggest that HSCT achieves complete mucosal healing in 50%, and that toxicity relates to the cyclophosphamide dose.

Design A UK multi-site RCT comparing low intensity HSCT with standard of care (SOC) in patients with active CD at endoscopy (SESCD ulcer score ≥ 2) refractory to 2 biologic classes. Planned recruitment was 99 patients randomised 2:1 to HSCT versus SOC. The primary endpoint was centrally read endoscopic remission (SESCD ulcer subscore of 0) without requirement for surgery or death at week 48.

Results The trial was halted due to unexpected SAE after 23 patients (13 HSCT, 10 SOC) had been randomised. The corona virus pandemic prevented some outcome assessments. Patients had advanced disease: mean (SD) CD duration 13.9 (7) years; CDAI at baseline 337.5 (182.4) with 20 (91%) having undergone surgery and 9 (43%) having a stoma. All patients contributed to the safety analysis. The primary outcome using central reading was available for 7/10 HSCT and 6/9 SOC patients. Absence of endoscopic ulceration without surgery or death was reported in 3/7 (43%) HSCT patients compared to 0/9 (0%) SOC patients. Absence read SESCD (mean (SD)) was 11.8 (8.7) and 10.1 (5.7) at baseline compared to 2.8 (2.9) and 18.7 (9.1) at week 48 in the HSCT and SOC groups respectively. Clinical remission (CDAI <150) occurred in 57% and 0% of patients in the HSCT and SOC groups at week 48. SAE were more frequent after HSCT (39 in 13 (100%) patients) than SOC (15 in 4 (40%) patients).

Importantly, 10 SUSARs were reported in 6 HSCT patients including 3 cases of delayed renal failure due to thrombotic microangiopathy (TMA). Two patients in the HSCT arm died. Conclusion HSCT using a low intensity regimen results in meaningful reduction in endoscopic disease activity with some patients experiencing resolution of ulceration. However, the incidence of serious adverse events makes the regimen used in this trial unsuitable for future clinical use.

This project (15/178/09) is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership. The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NIHR or the Department of Health and Social Care.

ADMISSION MODEL FOR INTENSIFICATION OF THERAPY IN ACUTE SEVERE COLITIS (ADMIT-ASC)

Alex Adams*, Vipin Gupta, Waled Mohsen, Thomas Chapman, Deoshan Subhaharan, Pradeep Ramaswamy, Oxford IBD Cohort Investigators, Vineet Ahuja, Simon Travis, Jack Satsangi.

1Translational Gastroenterology Unit, University of Oxford, Oxford, UK; 2Digestive Diseases Unit, Gold Coast University Hospital, Australia; 3Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India

10.1136/gutjnl-2021-BSG.7

Introduction Acute severe colitis (ASC) is an important cause of morbidity and mortality in UC, requiring hospitalisation and often colectomy. Accepted management is protocolised response assessment at Day 3 of IV steroid treatment. If steroid non-responders could be identified at all earlier stage, intensification may be possible prior to Day 3. It is also unclear whether ASC outcomes have changed over the past 25 years and we aimed to examine this.

Methods We examined ASC cohorts across 3 continents to produce an accurate predictor of steroid response. All patients received protocolised treatment including first-line IV corticosteroids, and endoscopic (UCEIS) scoring. Factors associated with requirement for rescue therapy, colectomy during admission, and the following year, and a composite measure of steroid response were identified by logistic regression in 131 adult ASC admissions in Oxford, UK, between 2015-9.